Tag: company

TORONTO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Petrolympic Ltd. (TSX-V: PCQ) (the “Company”), wishes to announce that the Company has applied to the TSX Venture Exchange (the “TSXV”) to extend the term of 3,100,000 common share purchase warrants originally issued pursuant to a private placement on September 8, 2025.

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Fly-E Group, Inc. (Nasdaq: FLYE) (“Fly-E” or the “Company”), an electric vehicle company engaged in designing, installing, selling, and renting smart electric motorcycles, electric bikes, and electric scooters, today announced the grand opening of its newest retail location in Boston, Massachusetts. The new store, now fully operational, marks the Company’s continued expansion in the Northeastern United States and underscores its mission to make safe, reliable, and eco-friendly transportation accessible to more communities.

Landmark listing makes Kyivstar the first and only publicly listed pure-play Ukrainian investment opportunity in the U.S. Stock Markets

CINCINNATI, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today reported financial results for the second quarter ended June 30, 2025.

Jennifer Callahan, Chief Financial Officer, appointed Interim CEO

Shrisha Radhakrishna appointed as President and interim leader of Opendoor

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

Virtual Events Include Investor Webinar and Presentation at Emerging Growth Conference 85

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

Joins Workhorse’s proven vehicles, manufacturing capabilities and national dealer network with Motiv’s diverse product portfolio and top fleet relationships

Continued progress across pipeline programs with focus on pancreatic cancer